Pilot Assessment of Soil-Transmitted Helminthiasis in the Context of Transmission Assessment Surveys for Lymphatic Filariasis in Benin and Tonga. A transmission assessment survey (TAS) is recommended to determine if MDA for LF can be stopped within an evaluation unit (EU) after at least five rounds of annual treatment. The TAS also provides an opportunity to simultaneously assess the impact of these MDAs on STH and to determine the frequency of school-based MDA for STH after community-wide MDA is no longer needed for LF.
To develop models that can predict MF prevalence after a given number of rounds of MDA as a tool to identify program settings in which the response to MDA is less than predicted.
Comparison of antigenemia by ICT and FTS RDT, antibody responses to Wb123 and Ov 16 by ELISA , and Wb123/Ov16 Biplex RDT on LF sentinel sites
To compare antigenemia results by ICT and FTS RDT, antibody responses to Wb123 and Ov 16 by ELISA , and Wb123/Ov16 Biplex RDT on LF sentinel sites.
Understanding Lymphatic Filariasis Antigenemia and Antibody responses in Sentinel sites post LF transmission interruption (The Gambia)
Assess Wb123 antibody responses in communities where LF transmission was interrupted without MDA.
The purpose of this study is to analyze the relationships among clinical signs (follicular trachoma) and the prevalence of infection and antibody and to determine whether it may be appropriate to consider one or more alternative indicators for deciding whether trachoma programs can stop MDA.
Field evaluation of two schistosome antibody-based rapid tests at point-of-care for prevalence mapping of urinary schistosomiasis in The Gambia
CCA Protocol: To know the sensitivity and specificity of POC CCA in the detection of urinary schistosomiasis, as compared to traditional diagnostic tools.
Field validation of sampling strategies for integrating STH surveys into Transmission Assessment Surveys (Ghana)
Test STH-TAS,Understand the age prevalence of LF Antibody in different setting.
To compare skin snip microfiladermia with antibody responses against Ov16 antigen in general population in epidemiological assessments post CDTi.